Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

OBJECTIVE: To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor necrosis factor (anti‐TNF) therapy....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Arthritis Rheumatol
Egile Nagusiak: Fleischmann, Roy, van Adelsberg, Janet, Lin, Yong, Castelar‐Pinheiro, Geraldo da Rocha, Brzezicki, Jan, Hrycaj, Pawel, Graham, Neil M. H., van Hoogstraten, Hubert, Bauer, Deborah, Burmester, Gerd R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Rheumatoid Arthritis
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6207906/
https://ncbi.nlm.nih.gov/pubmed/27860410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.39944
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak